Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Director | May 08, 2026 | May 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 08, 2026 · Filed May 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,997 |
Ending reported balance
After 2026-05-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-08 · Grant · Acquired 3,251 · Balance 7,933 F1: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Row 2 · 2026-05-08 · Grant · Acquired 1,064 · Balance 8,997 F2: This restricted stock award was granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 75,372 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 75,372 |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
F2: This restricted stock award was granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Xylem Inc.
Report date May 16, 2024 · Filed May 17, 2024
Section 16 reporting ended · disclosed 2024-05-17. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2026 Filed May 9, 2026 01:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005053 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,997 F2 · shares: This restricted stock award was granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 3,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005053 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,933 F1 · shares: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 09, 2025 Filed May 9, 2025 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004954 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,054 F2 · shares: This restricted stock award was granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 09, 2025 Filed May 9, 2025 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 3,528 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004954 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,900 F1 · shares: These restricted stock units were granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| February 14, 2025 Filed Feb 14, 2025 21:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionDirector Stock Option (Right to Acquire) · Derivative | 5,739 | $0.00 Strike: $45.32 | $0.00 |
DisclosureSEC source: 0001225208-25-001751 · doc4.xml · derivative · entry 4 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,739 shares Expires 2025-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 14, 2025 21:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,739 | $76.42 | $438,575.53 |
DisclosureSEC source: 0001225208-25-001751 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,372 F1 · price: This transaction was executed in multiple trades at prices ranging from $76.400 to $76.435. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 14, 2025 Filed Feb 14, 2025 21:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,739 | $45.32 | $260,072.54 |
DisclosureSEC source: 0001225208-25-001751 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2024 Filed May 9, 2024 23:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 999 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005898 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,372 F2 · shares: This restricted stock award was granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2024 Filed May 9, 2024 23:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 3,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005898 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,373 F1 · shares: These restricted stock units were granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 18, 2023 Filed May 22, 2023 22:09 UTC | Xylem Inc. XYL · Entity 430 | GrantCommon Stock | 1,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004395 · primarydocument.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,818 F1 · shares: Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in full on the trading day prior to the 2024 Annual Meeting of Shareholders. The Reporting Person has elected to defer the settlement of the RSU Award until Separation from Service Read SEC document |
| May 12, 2023 Filed May 15, 2023 22:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 898 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005908 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,318 F2 · shares: This restricted stock was granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 12, 2023 Filed May 15, 2023 22:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,803 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005908 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,420 F1 · shares: These restricted stock units were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 12, 2022 Filed May 16, 2022 22:45 UTC | Xylem Inc. XYL · Entity 430 | GrantCommon Stock | 1,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-029334 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,238 F1 · shares: Reflects the award of restricted stock units. The Reporting Person elected to defer the vesting of the RSU Award until Separation from Service. F2 · balance_after: Includes RSUs which the reporting person elected to defer the vesting of the award until Separation from Service. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 737 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006590 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,617 F2 · shares: This restricted stock was granted on May 4, 2022 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006590 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,880 F1 · shares: These restricted stock units were granted on May 4, 2022 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| December 14, 2021 Filed Feb 7, 2022 21:08 UTC | Xylem Inc. XYL · Entity 430 | GiftCommon Stock | 12,491 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007423 · doc5.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Steven R Loranger Revocable Trust Disclosed balance after: 46,407 F1 · shares: On December 14, 2021, 12,491 shares of Xylem Inc. common stock were transferred from the Steven R Loranger Revocable Trust to the Steve and Betsy Loranger Foundation. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:36 UTC | Xylem Inc. XYL · Entity 430 | GrantCommon Stock | 1,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032357 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,293 F1 · shares: Reflects the award of restricted stock units. The Reporting Person elected to defer the vesting event until separation of service. Read SEC document |
| May 05, 2021 Filed May 7, 2021 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantDirector Stock Option (Right to Acquire) · Derivative | 3,270 | $0.00 Strike: $91.77 | $0.00 |
DisclosureSEC source: 0001225208-21-007756 · doc4.xml · derivative · entry 3 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,270 Underlying: Common Stock · 3,270 shares Expires 2028-05-04 F2 · derivative.exercise_date: These options were granted on May 5, 2021 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007756 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,580 F1 · shares: These restricted stock units were granted on May 5, 2021 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on the Issuer's Board. Read SEC document |
| November 18, 2020 Filed Feb 1, 2021 15:59 UTC | Xylem Inc. XYL · Entity 430 | GiftCommon Stock | 13,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006383 · doc5.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Steven R Loranger Revokable Trust Disclosed balance after: 58,898 F1 · shares: On November 18, 2020, 13,545 shares of Xylem Inc. common stock were transferred from the Steven R Loranger Revocable Trust to the Steve and Betsy Loranger Foundation. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 23:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionDirector Stock Option (Right to Acquire) · Derivative | 19,797 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-20-013614 · doc4.xml · derivative · entry 3 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,797 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 23:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 19,797 | $35.20 | $696,789.07 |
DisclosureSEC source: 0001225208-20-013614 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 20:02 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 18,388 | $83.95 | $1,543,622.95 |
DisclosureSEC source: 0001209191-20-050449 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,098 F1 · price: This price represents the weighted average price per Share of the Issuer. Shares were sold at a prices ranging from $83.42 to $84.17. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| May 13, 2020 Filed May 14, 2020 19:11 UTC | Xylem Inc. XYL · Entity 430 | GrantCommon Stock | 2,577 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029103 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,965 F1 · shares: Reflects the award of restricted stock units. The Reporting Person elected to defer the vesting event until separation of service. F2 · balance_after: Includes the transfer of 6,088 shares from the reporting person's company savings plan. Read SEC document |
| May 08, 2020 Filed May 11, 2020 18:14 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantDirector Stock Option (Right to Acquire) · Derivative | 1,378 | $0.00 Strike: $217.84 | $0.00 |
DisclosureSEC source: 0001225208-20-007367 · doc4.xml · derivative · entry 3 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,378 Underlying: Common Stock · 1,378 shares Expires 2027-05-07 F2 · shares: These options were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date. F2 · derivative.exercise_date: These options were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date. Read SEC document |
| May 08, 2020 Filed May 11, 2020 18:14 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007367 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,056 F1 · shares: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 19:50 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 30,000 | $88.61 | $2,658,378.00 |
DisclosureSEC source: 0001209191-20-009556 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Steven R. Loranger Revocable Trust Disclosed balance after: 72,443 F1 · shares: 30,000 shares were sold from the Steven R. Loranger Revocable Trust. F2 · price: This price represents the approximate weighted average price per share of common stock (each a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $88.36 to $88.7150. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| November 14, 2019 Filed Feb 13, 2020 20:58 UTC | Xylem Inc. XYL · Entity 430 | GiftCommon Stock | 18,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009155 · doc5.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Steven R. Loranger Revocable Trust Disclosed balance after: 102,443 F1 · shares: On November 14, 2019, 18,475 shares of Xylem Inc. common stock were transferred from the Steven R Loranger Revocable Trust to the Steve and Betsy Loranger Foundation. Read SEC document |
| May 15, 2019 Filed May 17, 2019 19:52 UTC | Xylem Inc. XYL · Entity 430 | GrantCommon Stock | 1,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030835 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,909 F1 · shares: Reflects the award of restricted stock units. The Reporting Person elected to defer the vesting event until separation of service. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 414 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007859 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,955 F2 · shares: This restricted stock was granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested on March 15, 2020. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007859 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,541 F1 · shares: These restricted stock units were granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 20:19 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 10,000 | $76.99 | $769,917.00 |
DisclosureSEC source: 0001209191-19-019991 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Steven R. Loranger Revocable Trust Disclosed balance after: 120,918 F1 · shares: 10,000 shares were sold from the Steven R. Loranger Revocable Trust. F2 · price: This price represents the approximate weighted average price per share of common stock (each a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $76.81 to $77.1350. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| May 18, 2018 Filed May 22, 2018 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantDirector Stock Option (Right to Acquire) · Derivative | 1,913 | $0.00 Strike: $135.95 | $0.00 |
DisclosureSEC source: 0001225208-18-009754 · doc4.xml · derivative · entry 3 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,913 Underlying: Common Stock · 1,913 shares Expires 2025-05-17 F2 · shares: These options were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date. F2 · derivative.exercise_date: These options were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date. Read SEC document |
| May 18, 2018 Filed May 22, 2018 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009754 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,218 F1 · shares: These restricted stock units were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board. Read SEC document |
| May 09, 2018 Filed May 10, 2018 16:48 UTC | Xylem Inc. XYL · Entity 430 | GrantCommon Stock | 1,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-029118 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,078 F1 · shares: Reflects the award of restricted stock units, which are scheduled to vest on the business day prior to the Xylem Inc. 2019 annual shareholders' meeting. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 01:27 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,120 | $0.00 Strike: $32.38 | $0.00 |
DisclosureSEC source: 0001209191-17-066695 · doc4.xml · derivative · entry 7 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,120 shares Expires 2018-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 01:27 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 12,120 | $68.14 | $825,839.83 |
DisclosureSEC source: 0001209191-17-066695 · doc4.xml · nonDerivative · entry 4 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,131 F3 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $68.00 to $68.34 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 01:27 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionCommon Stock | 12,120 | $32.38 | $392,445.60 |
DisclosureSEC source: 0001209191-17-066695 · doc4.xml · nonDerivative · entry 3 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise and sale were made pursuant to a 10b5-1 plan adopted by the reporting person on November 10, 2017. Read SEC document |
| December 19, 2017 Filed Dec 21, 2017 01:27 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,019 | $0.00 Strike: $32.38 | $0.00 |
DisclosureSEC source: 0001209191-17-066695 · doc4.xml · derivative · entry 6 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,120 Underlying: Common Stock · 5,019 shares Expires 2018-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| December 19, 2017 Filed Dec 21, 2017 01:27 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 5,019 | $68.00 | $341,314.08 |
DisclosureSEC source: 0001209191-17-066695 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,131 F2 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $68.00 to $68.02 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| December 19, 2017 Filed Dec 21, 2017 01:27 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionCommon Stock | 5,019 | $32.38 | $162,515.22 |
DisclosureSEC source: 0001209191-17-066695 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise and sale were made pursuant to a 10b5-1 plan adopted by the reporting person on November 10, 2017. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 18:58 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionStock Option (Right to Buy) · Derivative | 47,712 | $0.00 Strike: $32.38 | $0.00 |
DisclosureSEC source: 0001209191-17-066272 · doc4.xml · derivative · entry 4 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,139 Underlying: Common Stock · 47,712 shares Expires 2018-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 18:58 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 47,712 | $68.10 | $3,248,958.18 |
DisclosureSEC source: 0001209191-17-066272 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,131 F2 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $68.00 to $68.35 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 18:58 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionCommon Stock | 47,712 | $32.38 | $1,544,914.56 |
DisclosureSEC source: 0001209191-17-066272 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise and sale were made pursuant to a 10b5-1 plan adopted by the reporting person on November 10, 2017. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 15:45 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $32.38 | $0.00 |
DisclosureSEC source: 0001209191-17-065805 · doc4.xml · derivative · entry 4 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,851 Underlying: Common Stock · 200 shares Expires 2018-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 15:45 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 200 | $68.02 | $13,604.00 |
DisclosureSEC source: 0001209191-17-065805 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,131 Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 15:45 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionCommon Stock | 200 | $32.38 | $6,476.00 |
DisclosureSEC source: 0001209191-17-065805 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise and sale were made pursuant to a 10b5-1 plan adopted by the reporting person on November 10, 2017. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:49 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionStock Option (Right to Buy) · Derivative | 196 | $0.00 Strike: $32.38 | $0.00 |
DisclosureSEC source: 0001209191-17-065495 · doc4.xml · derivative · entry 4 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,051 Underlying: Common Stock · 196 shares Expires 2018-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:49 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 196 | $68.23 | $13,373.08 |
DisclosureSEC source: 0001209191-17-065495 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,131 F2 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $68.07 to $68.39 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:49 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionCommon Stock | 196 | $32.38 | $6,346.48 |
DisclosureSEC source: 0001209191-17-065495 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise and sale were made pursuant to a 10b5-1 plan adopted by the reporting person on November 10, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.